Overview
- The FDA granted an expanded indication for Eli Lilly’s diabetes drug Mounjaro to help prevent heart attacks and strokes in high‑risk adults with type 2 diabetes.
- The approval was driven by the SURPASS‑CVOT head‑to‑head trial that compared Mounjaro directly with dulaglutide (Trulicity) and reported roughly an 8% relative reduction in major heart events.
- Because the trial used an active comparator rather than placebo, the 8% figure measures benefit over another proven drug and is not directly comparable to larger reductions reported in placebo‑controlled trials of other medicines.
- Regulators and researchers continue safety monitoring using spontaneous reports such as the UK Yellow Card totals, which signal suspected problems but do not prove a causal link.
- The label change strengthens Lilly’s commercial position—Mounjaro/Zepbound has driven steep sales growth—and the company is pursuing follow‑up studies and next‑generation multi‑hormone drugs to test broader cardiovascular and weight‑loss effects.